Cargando…

Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer

BACKGROUND: In 2017, Massachusetts General Hospital implemented the Severe Immunotherapy Complications (SIC) Service, a multidisciplinary care team for patients hospitalized with immune-related adverse events (irAEs), a unique spectrum of toxicities associated with immune checkpoint inhibitors (ICIs...

Descripción completa

Detalles Bibliográficos
Autores principales: Zubiri, Leyre, Molina, Gabriel E, Mooradian, Meghan J, Cohen, Justine, Durbin, Sienna M, Petrillo, Laura, Boland, Genevieve M, Juric, Dejan, Dougan, Michael, Thomas, Molly F, Faje, Alex T, Rengarajan, Michelle, Guidon, Amanda C, Chen, Steven T, Okin, Daniel, Medoff, Benjamin D, Nasrallah, Mazen, Kohler, Minna J, Schoenfeld, Sara R, Leaf, Rebecca K, Sise, Meghan E, Neilan, Tomas G, Zlotoff, Daniel A, Farmer, Jocelyn R, Bardia, Aditya, Sullivan, Ryan J, Blum, Steven M, Semenov, Yevgeniy R, Villani, Alexandra-Chloé, Reynolds, Kerry L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454442/
https://www.ncbi.nlm.nih.gov/pubmed/34544895
http://dx.doi.org/10.1136/jitc-2021-002886
_version_ 1784570494120361984
author Zubiri, Leyre
Molina, Gabriel E
Mooradian, Meghan J
Cohen, Justine
Durbin, Sienna M
Petrillo, Laura
Boland, Genevieve M
Juric, Dejan
Dougan, Michael
Thomas, Molly F
Faje, Alex T
Rengarajan, Michelle
Guidon, Amanda C
Chen, Steven T
Okin, Daniel
Medoff, Benjamin D
Nasrallah, Mazen
Kohler, Minna J
Schoenfeld, Sara R
Leaf, Rebecca K
Sise, Meghan E
Neilan, Tomas G
Zlotoff, Daniel A
Farmer, Jocelyn R
Bardia, Aditya
Sullivan, Ryan J
Blum, Steven M
Semenov, Yevgeniy R
Villani, Alexandra-Chloé
Reynolds, Kerry L
author_facet Zubiri, Leyre
Molina, Gabriel E
Mooradian, Meghan J
Cohen, Justine
Durbin, Sienna M
Petrillo, Laura
Boland, Genevieve M
Juric, Dejan
Dougan, Michael
Thomas, Molly F
Faje, Alex T
Rengarajan, Michelle
Guidon, Amanda C
Chen, Steven T
Okin, Daniel
Medoff, Benjamin D
Nasrallah, Mazen
Kohler, Minna J
Schoenfeld, Sara R
Leaf, Rebecca K
Sise, Meghan E
Neilan, Tomas G
Zlotoff, Daniel A
Farmer, Jocelyn R
Bardia, Aditya
Sullivan, Ryan J
Blum, Steven M
Semenov, Yevgeniy R
Villani, Alexandra-Chloé
Reynolds, Kerry L
author_sort Zubiri, Leyre
collection PubMed
description BACKGROUND: In 2017, Massachusetts General Hospital implemented the Severe Immunotherapy Complications (SIC) Service, a multidisciplinary care team for patients hospitalized with immune-related adverse events (irAEs), a unique spectrum of toxicities associated with immune checkpoint inhibitors (ICIs). This study’s objectives were to evaluate the intervention’s (1) effect on patient outcomes and healthcare utilization, and (2) ability to collect biological samples via a central infrastructure, in order to study the mechanisms responsible for irAEs. METHODS: A hospital database was used to identify patients who received ICIs for a malignancy and were hospitalized with severe irAEs, before (April 2, 2016–October 3, 2017) and after (October 3, 2017–October 24, 2018) SIC Service initiation. The primary outcome was readmission rate after index hospitalization. Secondary outcomes included length of stay (LOS) for admissions, corticosteroid and non-steroidal second-line immunosuppression use, ICI discontinuation, and inpatient mortality. RESULTS: In the pre-SIC period, 127 of 1169 patients treated with ICIs were hospitalized for irAEs; in the post-SIC period, 122 of 1159. After SIC service initiation, reductions were observed in irAE readmission rate (14.8% post-SIC vs 25.9% pre-SIC; OR 0.46; 95% CI 0.22 to 0.95; p=0.036) and readmission LOS (median 6 days post-SIC vs 7 days pre-SIC; 95% CI −16.03 to –0.14; p=0.046). No significant pre-initiation and post-initiation differences were detected in corticosteroid use, second-line immunosuppression, ICI discontinuation, or inpatient mortality rates. The SIC Service collected 789 blood and tissue samples from 234 patients with suspected irAEs. CONCLUSIONS: This is the first study to report that establishing a highly subspecialized care team focused on irAEs is associated with improved patient outcomes and reduced healthcare utilization. Furthermore, the SIC Service successfully integrated blood and tissue collection safety into routine care.
format Online
Article
Text
id pubmed-8454442
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-84544422021-10-13 Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer Zubiri, Leyre Molina, Gabriel E Mooradian, Meghan J Cohen, Justine Durbin, Sienna M Petrillo, Laura Boland, Genevieve M Juric, Dejan Dougan, Michael Thomas, Molly F Faje, Alex T Rengarajan, Michelle Guidon, Amanda C Chen, Steven T Okin, Daniel Medoff, Benjamin D Nasrallah, Mazen Kohler, Minna J Schoenfeld, Sara R Leaf, Rebecca K Sise, Meghan E Neilan, Tomas G Zlotoff, Daniel A Farmer, Jocelyn R Bardia, Aditya Sullivan, Ryan J Blum, Steven M Semenov, Yevgeniy R Villani, Alexandra-Chloé Reynolds, Kerry L J Immunother Cancer Clinical/Translational Cancer Immunotherapy BACKGROUND: In 2017, Massachusetts General Hospital implemented the Severe Immunotherapy Complications (SIC) Service, a multidisciplinary care team for patients hospitalized with immune-related adverse events (irAEs), a unique spectrum of toxicities associated with immune checkpoint inhibitors (ICIs). This study’s objectives were to evaluate the intervention’s (1) effect on patient outcomes and healthcare utilization, and (2) ability to collect biological samples via a central infrastructure, in order to study the mechanisms responsible for irAEs. METHODS: A hospital database was used to identify patients who received ICIs for a malignancy and were hospitalized with severe irAEs, before (April 2, 2016–October 3, 2017) and after (October 3, 2017–October 24, 2018) SIC Service initiation. The primary outcome was readmission rate after index hospitalization. Secondary outcomes included length of stay (LOS) for admissions, corticosteroid and non-steroidal second-line immunosuppression use, ICI discontinuation, and inpatient mortality. RESULTS: In the pre-SIC period, 127 of 1169 patients treated with ICIs were hospitalized for irAEs; in the post-SIC period, 122 of 1159. After SIC service initiation, reductions were observed in irAE readmission rate (14.8% post-SIC vs 25.9% pre-SIC; OR 0.46; 95% CI 0.22 to 0.95; p=0.036) and readmission LOS (median 6 days post-SIC vs 7 days pre-SIC; 95% CI −16.03 to –0.14; p=0.046). No significant pre-initiation and post-initiation differences were detected in corticosteroid use, second-line immunosuppression, ICI discontinuation, or inpatient mortality rates. The SIC Service collected 789 blood and tissue samples from 234 patients with suspected irAEs. CONCLUSIONS: This is the first study to report that establishing a highly subspecialized care team focused on irAEs is associated with improved patient outcomes and reduced healthcare utilization. Furthermore, the SIC Service successfully integrated blood and tissue collection safety into routine care. BMJ Publishing Group 2021-09-20 /pmc/articles/PMC8454442/ /pubmed/34544895 http://dx.doi.org/10.1136/jitc-2021-002886 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Clinical/Translational Cancer Immunotherapy
Zubiri, Leyre
Molina, Gabriel E
Mooradian, Meghan J
Cohen, Justine
Durbin, Sienna M
Petrillo, Laura
Boland, Genevieve M
Juric, Dejan
Dougan, Michael
Thomas, Molly F
Faje, Alex T
Rengarajan, Michelle
Guidon, Amanda C
Chen, Steven T
Okin, Daniel
Medoff, Benjamin D
Nasrallah, Mazen
Kohler, Minna J
Schoenfeld, Sara R
Leaf, Rebecca K
Sise, Meghan E
Neilan, Tomas G
Zlotoff, Daniel A
Farmer, Jocelyn R
Bardia, Aditya
Sullivan, Ryan J
Blum, Steven M
Semenov, Yevgeniy R
Villani, Alexandra-Chloé
Reynolds, Kerry L
Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
title Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
title_full Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
title_fullStr Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
title_full_unstemmed Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
title_short Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
title_sort effect of a multidisciplinary severe immunotherapy complications service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
topic Clinical/Translational Cancer Immunotherapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454442/
https://www.ncbi.nlm.nih.gov/pubmed/34544895
http://dx.doi.org/10.1136/jitc-2021-002886
work_keys_str_mv AT zubirileyre effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT molinagabriele effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT mooradianmeghanj effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT cohenjustine effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT durbinsiennam effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT petrillolaura effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT bolandgenevievem effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT juricdejan effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT douganmichael effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT thomasmollyf effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT fajealext effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT rengarajanmichelle effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT guidonamandac effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT chenstevent effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT okindaniel effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT medoffbenjamind effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT nasrallahmazen effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT kohlerminnaj effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT schoenfeldsarar effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT leafrebeccak effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT sisemeghane effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT neilantomasg effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT zlotoffdaniela effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT farmerjocelynr effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT bardiaaditya effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT sullivanryanj effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT blumstevenm effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT semenovyevgeniyr effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT villanialexandrachloe effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer
AT reynoldskerryl effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer